Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More

For Exact Sciences (NASDAQ: EXAS), good news came in the form of an acquisition bid. Healthcare giant Abbott Labs (NYSE: ABT) entered into a definitive agreement with Exact Sciences to buy the cancer screening and diagnostic test specialist. Under the terms of the deal, Abbott will pay $105 per share for Exact Sciences, an amount that represents a 22% premium to the closing price of Exact Sciences shares on Wednesday afternoon before the acquisition bid. For Abbott, the combination will broaden its cancer d ...